Themis Medicare share news, announcements and annual reports
NSE: THEMISMEDBSE: 530199Pharmaceuticals & BiotechnologySmall Cap
Themis Medicare Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Apr 2007 on NSE
Last close ₹94.83down ₹2.69 (2.76%)BSE ₹95.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹97.52.
30 Oct: open ₹97.39, high ₹99.58, low ₹94.02
52-week range of traded prices to 30 Oct 2026
₹64.95Low, 30 Mar 2026₹140.60High, 7 Sep 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹873 Cr1,570th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.85
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹92 crore of one-off items, the largest of them in the quarter to Jun 2026.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.19
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹92 crore of one-off items, the largest of them in the quarter to Jun 2026.
- −13.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −10.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,90035.0% delivered
Themis Medicare share news and announcements
714 announcements, routine notices left out, newest first. Page 12 of 15.
Apr 2015
Mar 2015
10 Mar · Board meeting
To review the normal business operations of the Company.
Feb 2015
9 Feb · Business
Jan 2015
Nov 2014
5 Nov · Updates
With reference to Company's letter dated September 17, 2013 intimating Exchange on execution of Supply & Distribution Agreement dated August 16, 2013 between the Company and Novartis India Limited ("Novartis") for Supply of Diclofenac Sodium 75 mg per ml Injection as finished dosage pharmaceutical form. Further it is informed that in terms of this agreement, Company has commenced supply to Novartis from October 2014
Oct 2014
20 Oct · Board meeting
To consider, inter alia, the Unaudited Financial Results for the quarter ended September 30, 2014.1 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2014
29 Sep · Business
Board of Directors of the Company at its meeting held on September 29, 2014 approved the allotment of 8660 Equity Shares of Rs.10/- each fully paid up to employees who have exercised their option under THEMIS MEDICARE ESOS, 2012.25 Sep · Board meeting
To transact, inter alia, to allot Equity Shares to eligible employees of the Company, who have exercised the ESOP options.8 Sep · Updates
Company is pleased to announce supply of its research based product, for pain management (API - Aceclofenac based injection) to a Indian Pharma major, under long term agreement. Themis is the first Company to develop this injection which is IPR protected.
Aug 2014
7 Aug · Meeting
Share Transfer Register & Register of Members will remain closed from September 23, 2014 to September 29, 2014 (both days inclusive) for the purpose of Annual General Meeting to be held on September 29, 2014.7 Aug · Board meeting
Board of Directors at its meeting held on August 06, 2014: (1) Ms. Dharmishta N. Raval was appointed by the Board as Additional Director being Independent Women Director w. e. f August 06, 2014. (2) Mr. Hariharan Subramaniam, Independent Director, was appointed as a member of Remuneration & Compensation Committee. Stakeholder's Relationship Committee was formed with Mr. Hariharan Subramaniam as Chairman and Sachin D. Patel & Mr. Rajneesh Anand as Committee members.
Jul 2014
28 Jul · Board meeting
To consider, inter alia, the Unaudited Financial Results for the quarter ended June 30, 2014.
May 2014
14 May · Board meeting
Board of Directors of the Company at its meeting held on May 14, 2014 has approved the following:(1) Independent Directors Mr. Hoshang N. Sinor, Mr. Humayun Dhanrajgir & Mr. Vijay Agarwal are further reappointed for a period of five years.In view of no activity Wholly owned foreign subsidiary HIDPUL Kft, Hungary will be stopped operationally with immediate effect, subject to following rules in the country of Incorporation i.e. Hungary
Apr 2014
1 Apr · Board meeting
Mar 2014
19 Mar · Board meeting
Feb 2014
10 Feb · Results
Jan 2014
15 Jan · Board meeting
At the meeting of the Board of Directors held on January 15, 2014 following proposals were approved :- (1) Conversion of 400000 optionally convertible Preferential warrants of Rs.10/- each at a premium of Rs. 75/- issued to some of the Indian Promoters into 1 fully paid equity share of Rs. 10 each at a premium of Rs. 75/- per share as per provisions of SEBI (Issue of capital & Disclosure Requirements) Regulations 2009; (2) The Board also noted commencement of supply to Novartis India Limited of Diclofenac Topical Gel using TPM Transdermal Drug Delivery System in finished dosage pharmaceutical form as per agreement entered with them on March 26, 2013.3 Jan · Board meeting
To consider and approve the conversion of Preferential Warrants issued to the Promoters on July 16, 2012 into equity shares on completion of 18 months.
Nov 2013
11 Nov · Results
Oct 2013
31 Oct · Board meeting
Meeting of the Board of Directors of the Company will be held on November 11, 2013 preceded by a meeting of the Audit Committee, to consider and approve inter alia, the Unaudited Financial Results together with Limited Review Report submitted by the Statutory Auditors of the Company for the quarter ended September 30, 2013.
Sep 2013
Aug 2013
Jul 2013
31 Jul · Board meeting
To consider and approve inter alia, the Unaudited Financial Results together with Limited Review Report submitted by the Statutory Auditors of the Company for the quarter ended June 30, 2013.15 Jul · Meeting
Company has fixed Book Closure from August 23, 2013 to August 30, 2013 (Both days inclusive) for the purpose of Annual General Meeting to be held on August 30, 2013.
May 2013
3 May · Board meeting
Meeting of the Board of Directors of the Company will be held on May 15, 2013 preceded by a meeting of the Audit Committee, to consider, inter alia, the Audited Financial Results for the year ended March 31, 2013.
Apr 2013
Feb 2013
Jan 2013
22 Jan · Board meeting
Meeting of the Board of Directors of the Company will be held on February 05, 2013 preceded by a meeting of the Audit Committee, to consider, inter alia, the Un-audited Financial Results for the quarter ended December 31, 2012.
Nov 2012
Oct 2012
30 Oct · Board meeting
Meeting of the Board of Directors of the Company will be held on November 10, 2012 preceded by a meeting of the Audit Committee, to consider, inter alia, the Unaudited Financial Results for the quarter ended September 30, 2012.